15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 6 firms covering Immunic Inc, 5 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. The target range is very wide, $2.50 to $27.00 (about 10.8x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $10.92 sits 18% below the current $13.31. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.19 next quarter toward $-3.56 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 ratings
Strong Buy
Strong Buy00%
Buy583%
Hold117%
Sell00%
Strong Sell00%
Based on 6 analysts giving stock ratings to Immunic Inc.
As of Jul, 5 of 6 firms rate IMUX a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
IMUX EPS & revenue forecast
EPS · NEXT QUARTER
$-1.19
Range $-2.21 – $-0.68 · 9 analysts · -8% YoY
Next period, 9 analysts expect Immunic Inc to earn $-1.19 a share (range $-2.21 – $-0.68), versus $-1.30 a year earlier. Full-year consensus is $-4.41, growing to $-3.56 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 9 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $11.1M next year.
Top analysts covering Immunic Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on IMUX.
#1
Yatin Suneja
Guggenheim · Rank #28
Buy
$70.00+425.9% to target
Overall win rate
52%
+ Follow
#2
MC
Matthew Caufield
HC Wainwright & Co. · Rank #51
Buy
$22.00+65.3% to target
Overall win rate
56%
+ Follow
#3
Jason Kolbert
D. Boral Capital · Rank #346
Hold
No targeton IMUX
Overall win rate
22%
+ Follow
#4
Aydin Huseynov
Ladenburg Thalmann · Rank #361
Buy
$30.00+125.4% to target
Overall win rate
34%
+ Follow
#5
WW
William Woods
B. Riley Securities
Buy
$27.00+102.9% to target
Coverage
—
+ Follow
IMUX stock forecast FAQ
What is IMUX's average 12-month price target?+
The 5 analysts with a live target average $10.92 for Immunic Inc over the next 12 months, ranging from a $27.00 high to a $2.50 low.
Is IMUX stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 6 analyst ratings, 5 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for IMUX?+
The Street-high target is $27.00 (B. Riley Securities), and the Street-low is $2.50 (Stifel). The average of all 5 active targets is $10.92.
How many Wall Street analysts cover IMUX?+
6 analysts have an active rating on Immunic Inc, and 5 firms carry a live 12-month price target.
Who is the most accurate analyst covering IMUX?+
Among analysts who currently cover IMUX, Yatin Suneja of Guggenheim has the strongest overall Quantellect track record (Rank #28). Their current call is Buy with a $70.00 target.
What is Immunic Inc's projected EPS for next quarter?+
The consensus estimate is $-1.19 per share (range $-2.21 – $-0.68) across 9 analysts. Full-year EPS is projected at $-4.41, rising to $-3.56 the following year.
How much revenue is Immunic Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $11.1M next year.
Have analysts been upgrading or downgrading IMUX lately?+
As of Jul, 5 of 6 firms rate IMUX a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their IMUX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
